Abbas Hussain - 02 Oct 2024 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
/s/ Brian Sandstrom, As Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
02 Oct 2024
Net transactions value
$0
Form type
4
Filing time
04 Oct 2024, 08:52:56 UTC
Previous filing
20 Feb 2024
Next filing
02 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +8,093 $0.000000 8,093 02 Oct 2024 Common Stock 8,093 $63.16 Direct F1
transaction MRNA Stock Option (Right to Buy) Award $0 +5,100 $0.000000 5,100 02 Oct 2024 Common Stock 5,100 $63.16 Direct F2
transaction MRNA Restricted Stock Units Award $0 +1,439 $0.000000 1,439 02 Oct 2024 Common Stock 1,439 Direct F3, F4
transaction MRNA Restricted Stock Units Award $0 +892 $0.000000 892 02 Oct 2024 Common Stock 892 Direct F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option will become fully vested and exercisable on October 2, 2025.
F2 This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
F3 Restricted stock units convert into common stock on a one-for-one basis.
F4 The shares subject to this restricted stock unit award will vest in full on October 2, 2025.
F5 The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.